O'Kane Sharon
Known title: DirectorCIK: 0001655980
Associated companies
Transaction History
| LIVN | ▲ Buy | Option Exercise | 3,416 | $0 | 6/15/2025 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 1,606 | $73K | 6/15/2025 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 2,680 | $0 | 6/15/2024 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 1,260 | $66K | 6/15/2024 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 2,082 | $0 | 6/15/2023 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 979 | $47K | 6/15/2023 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 1,346 | $0 | 6/15/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 636 | $38K | 6/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
LivaNova Shares Rise on Barclays Overweight Rating
Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.
LivaNova Shares Rise on Barclays Overweight Rating. Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.